About Marina Biotech (OTCMKTS:MRNA)
Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company's pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales28.43
Price / CashN/A
Book Value$0.36 per share
Price / Book5.11
Return on Equity-139.40%
Return on Assets-59.40%
Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions
What is Marina Biotech's stock symbol?
Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."
How were Marina Biotech's earnings last quarter?
Marina Biotech, Inc. (OTCMKTS:MRNA) posted its quarterly earnings data on Monday, November, 13th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. View Marina Biotech's Earnings History.
When will Marina Biotech make its next earnings announcement?
Who are some of Marina Biotech's key competitors?
Some companies that are related to Marina Biotech include Rewalk Robotics (RWLK), Cesca Therapeutics (KOOL), Oncobiologics (ONS), Tonix Pharmaceuticals (TNXP), Prana Biotechnology (PRAN), RegeneRx Biopharmaceuticals (RGRX), Valeritas (VLRX), Eyegate Pharmaceuticals (EYEG), Soligenix (SNGX), Innovus Pharmaceuticals (INNV), Critical Outcome T (COTQF), Windtree Therapeutics (WINT), Acura Pharmaceuticals (ACUR), Jaguar Health (JAGX), Callitas Health In (MPHMF), Sunshine Heart (CHFS), ESSA Pharma (EPIX) and Strata Skin Sciences (SSKN).
Who are Marina Biotech's key executives?
Marina Biotech's management team includes the folowing people:
- Vuong Trieu Ph.D., Executive Chairman of the Board (Age 51)
- Joseph W. Ramelli, Chief Executive Officer, Secretary (Age 48)
- Amit Shah, Chief Financial Officer
- Mihir Munsif, Chief Operating Officer (Age 54)
- Larn Hwang Ph.D., Chief Scientific Officer (Age 54)
- Erik Emerson, Chief Commercial Officer
- Peter D. Weinstein Ph.D., Chief Legal Officer
- Isaac Blech, Director
- Philippe Calais Ph.D, Director
How do I buy Marina Biotech stock?
Shares of Marina Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marina Biotech's stock price today?
One share of Marina Biotech stock can currently be purchased for approximately $1.84.
How big of a company is Marina Biotech?
Marina Biotech has a market capitalization of $18.94 million and generates $680,000.00 in revenue each year. Marina Biotech employs 4 workers across the globe.
How can I contact Marina Biotech?
Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]
MarketBeat Community Rating for Marina Biotech (MRNA)MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Marina Biotech (OTCMKTS:MRNA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Marina Biotech (OTCMKTS:MRNA) Earnings History and Estimates Chart
Marina Biotech (OTCMKTS MRNA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/30/2018|| || || || || || || || |
|11/21/2016||Q3 2016||($0.05)||$0.05 million||View||N/A|
Marina Biotech (OTCMKTS:MRNA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Marina Biotech (OTCMKTS:MRNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Marina Biotech (OTCMKTS MRNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 50.00%
Marina Biotech (OTCMKTS MRNA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/9/2017||Vuong Trieu||Chairman||Buy||10,000||$0.39||$3,900.00||11,127,141|| |
|6/7/2017||Vuong Trieu||Chairman||Buy||22,500||$0.39||$8,775.00||11,117,141|| |
|4/6/2017||Joseph W Ramelli||CEO||Buy||35,500||$0.39||$13,845.00||440,653|| |
|4/5/2017||Joseph W Ramelli||CEO||Buy||97,550||$0.31||$30,240.50||405,153|| |
|2/6/2017||Vuong Trieu||Chairman||Buy||862,068||$0.29||$249,999.72||11,094,641|| |
|4/16/2014||Joseph W Ramelli||Director||Buy||26,300||$0.76||$19,988.00|| |
|2/10/2014||Cashman Llp Pryor||Major Shareholder||Sell||108,041||$0.99||$106,960.59|| |
|10/4/2013||Cashman Llp Pryor||Major Shareholder||Sell||100,000||$0.25||$25,000.00|| |
Marina Biotech (OTCMKTS MRNA) News Headlines
|Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio|
finance.yahoo.com - January 16 at 9:34 AM
|Marina Biotech (MRNA) Lowered to Sell at ValuEngine|
www.americanbankingnews.com - December 3 at 6:30 AM
|Marina Biotech Appoints Isaac Blech to its Board of Directors|
finance.yahoo.com - November 27 at 3:45 PM
|Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives|
finance.yahoo.com - October 20 at 6:29 AM
|Marina Biotech Appoints Amit Shah as Chief Financial Officer|
finance.yahoo.com - October 5 at 8:59 AM
|Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives|
finance.yahoo.com - August 21 at 8:06 PM
|Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market|
finance.yahoo.com - August 3 at 5:57 AM
|Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform|
finance.yahoo.com - July 26 at 1:11 AM
|Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®|
finance.yahoo.com - July 25 at 4:06 AM
|Marina Biotech up 11% on SMARTICLES license deal|
seekingalpha.com - July 20 at 1:44 AM
|Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics|
finance.yahoo.com - July 20 at 1:44 AM
|Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman|
finance.yahoo.com - July 5 at 8:41 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Off|
biz.yahoo.com - February 14 at 8:15 PM
|Marina Biotech Announces a License Agreement to SMARTICLES|
us.rd.yahoo.com - February 7 at 7:58 PM
|10:28 am Marina Biotech (thinly-traded) entered into a license agreement regarding its SMARTICLES platform; could receive up to $90 mln in success based milestones|
us.rd.yahoo.com - February 7 at 7:58 PM
|MARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements a|
biz.yahoo.com - January 28 at 1:50 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events|
biz.yahoo.com - December 14 at 7:19 PM
|MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dis|
biz.yahoo.com - November 18 at 5:51 PM
|Marina Biotech (MRNA) to Merge with IthenaPharma|
www.streetinsider.com - November 16 at 9:56 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - August 1 at 9:17 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - June 24 at 9:17 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - June 2 at 9:58 AM
Marina Biotech (OTCMKTS:MRNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Marina Biotech (OTCMKTS:MRNA) Income Statement, Balance Sheet and Cash Flow Statement
Marina Biotech (OTCMKTS MRNA) Stock Chart for Wednesday, January, 17, 2018